Avalyn Pharma Inc. Common Stock (AVLN)
AVLN Stock Price Chart
Explore Avalyn Pharma Inc. Common Stock interactive price chart. Choose custom timeframes to analyze AVLN price movements and trends.
AVLN Company Profile
Discover essential business fundamentals and corporate details for Avalyn Pharma Inc. Common Stock (AVLN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
30 Apr 2026
Employees
50.00
Website
http://www.avalynpharma.comCEO
Lyn Baranowski
Description
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
AVLN Financial Timeline
Browse a chronological timeline of Avalyn Pharma Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.58.
Earnings released on 3 Jun 2026
EPS came in at -$21.83 falling short of the estimated -$5.98 by -265.25%.
AVLN Stock Performance
Access detailed AVLN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
